Post-Traumatic Stress Disorder (PTSD) – Opportunity Analysis and Forecasts to 2028

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 PTSD: Executive Summary

2.1 Double-Digit Growth Expected in PTSD Market from 2018–2028

2.2 Focus Is on Label Expansion, Comorbidities, and Novel Mechanisms of Action in PTSD Pipeline

2.3 Lack of Efficacious Pharmacotherapeutic Options Is a Major Unmet Need

2.4 Brexpiprazole and Midomafetamine to Be Top-Selling Drugs in 2028

2.5 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Classification or Staging Systems

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources Used

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for PTSD (2018–2028)

5.5.1 12-Month Total Prevalent Cases of PTSD

5.5.2 Age-Specific 12-Month Total Prevalent Cases of PTSD

5.5.3 Sex-Specific 12-Month Total Prevalent Cases of PTSD

5.5.4 12-Month Total Prevalent Cases of PTSD by Onset of Disease

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of Analysis

5.6.3 Strengths of Analysis

6 Current Treatment Options

6.1 Overview

6.2 Psychotherapy

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Improved Efficacy of Available Treatments

7.3 Improving Side-Effect Profiles and Patient Compliance

7.4 Increased Access to Treatment for Vulnerable Populations

7.5 Clearer Diagnostic Guidelines

8 R&D Strategies

8.1 Overview

8.1.1 Repurposing Atypical Antipsychotics and Other Marketed Drugs

8.1.2 Drug Candidates with Novel Mechanisms of Action

8.1.3 Targeting Key Comorbidities of PTSD

8.2 Clinical Trials Design

8.2.1 The Preference for Straightforward Treatment Regimens

8.2.2 The Interplay of Psychotherapeutic and Pharmacotherapeutic Strategies

8.2.3 Studying Off-Label Therapeutics to Generate Reliable Clinical Data

9 Pipeline Assessment

9.1 Overview

9.2 Innovative Early-Stage Approaches

9.3 Other Drugs in Development

10 Pipeline Valuation Analysis

10.1 Clinical Benchmark of Key Pipeline Drugs

10.2 Commercial Benchmark of Key Pipeline Drugs

10.3 Competitive Assessment

10.4 Top-Line 10-Year Forecast

10.4.1 US

10.4.2 5EU

10.4.3 Japan

11 Appendix

11.1 Bibliography

11.2 Abbreviations

11.3 Methodology

11.3.1 Forecasting Methodology

11.3.2 Diagnosed Patients

11.3.3 Percent Drug-Treated Patients

11.3.4 Drugs Included in Each Therapeutic Class

11.3.5 Launch and Patent Expiry Dates

11.3.6 General Pricing Assumptions

11.3.7 Individual Drug Assumptions

11.3.8 Generic Erosion

11.3.9 Pricing of Pipeline Agents

11.4 Primary Research – KOLs Interviewed for This Report

11.4.1 KOLs

11.5 Primary Research – Prescriber Survey

11.6 About the Authors

11.6.1 Analyst

11.6.2 Therapy Area Director

11.6.3 Epidemiologist

11.6.4 Reviewers

11.6.5 Global Director of Therapy Analysis and Epidemiology

11.6.6 Global Head and EVP of Healthcare Operations and Strategy

11.7 About GlobalData

11.8 Contact Us

11.9 Disclaimer

Table 1: Post-Traumatic Stress Disorder: Key Metrics in the 7MM

Table 2: Overview of PTSD symptoms included in DSM-5

Table 3: Risk Factors and Comorbid Conditions Associated with PTSD

Table 4: Off-Label Drugs for PTSD in the 7MM

Table 5: Treatment Guidelines for PTSD

Table 6: Approved Treatments for PTSD, 2019

Table 7: Comparison of Therapeutic Classes in Development for PTSD, 2018–2028

Table 8: Innovative Early-Stage Approaches for PTSD, 2019

Table 9: Drugs in Development for PTSD, 2019

Table 10: Clinical Benchmark of Key Pipeline Drugs – PTSD

Table 11: Commercial Benchmark of Key Pipeline Drugs – PTSD

Table 12: Key Events Impacting Global Sales for PTSD, 2018–2028

Table 13: PTSD Market – Global Drivers and Barriers, 2018–2028

Table 14: Key Historical and Projected Launch Dates for PTSD

Table 15: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figure 1: Global Sales Forecast by Country for PTSD in 2018 and 2028

Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Zoloft

Figure 3: Fight-or-Flight Response Overview and Pathophysiological Aspects of PTSD

Figure 4: 7MM, 12-Month Total Prevalence of PTSD (%), Men and Women, Ages ≥18 Years, 2018

Figure 5: 7MM, Sources Used and Not Used to Forecast the 12-Month Total Prevalent Cases of PTSD

Figure 6: 7MM, Sources Used to Forecast the 12-Month Total Prevalent Cases of PTSD by Onset of Disease

Figure 7: 7MM, 12-Month Total Prevalent Cases of PTSD, Both Sexes, Ages ≥18 Years, 2018

Figure 8: 7MM, Age-Specific 12-Month Total Prevalent Cases of PTSD, Both Sexes, Ages ≥18 Years, 2018

Figure 9: 7MM, Sex-Specific 12-Month Total Prevalent Cases of PTSD, Ages ≥18 Years, 2018

Figure 10: 7MM, 12-Month Total Prevalent Cases of PTSD by Onset of Disease, Both Sexes, Ages ≥18 Years, 2018

Figure 11: Unmet Needs and Opportunities in PTSD

Figure 12: Overview of the Development Pipeline in PTSD

Figure 13: Key Phase II/III Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for PTSD in the 7MM During the Forecast Period

Figure 14: Competitive Assessment of the Marketed and Pipeline PTSD Drugs Benchmarked Against the SOC, Zoloft

Figure 15: Global (7MM) Sales Forecast by Country for PTSD in 2018 and 2028

Figure 16: Global Sales Forecast by Brand for PTSD in 2018 and 2028

Figure 17: Sales Forecast by Brand for PTSD in the US in 2018 and 2028

Figure 18: Sales Forecast by Brand for PTSD in the 5EU Markets in 2018 and 2028

Figure 19: Sales Forecast by Brand for PTSD in Japan in 2018 and 2028